Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $3.9167.

FATE has been the subject of several research reports. HC Wainwright raised shares of Fate Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fate Therapeutics in a research note on Thursday, January 22nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Fate Therapeutics in a research report on Tuesday, November 4th. Wedbush raised Fate Therapeutics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $5.00 to $7.00 in a report on Monday, October 27th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Monday, October 27th.

Institutional Investors Weigh In On Fate Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Savant Capital LLC bought a new position in shares of Fate Therapeutics in the second quarter worth approximately $27,000. Bridgeway Capital Management LLC bought a new position in Fate Therapeutics in the 2nd quarter worth $28,000. Russell Investments Group Ltd. increased its stake in Fate Therapeutics by 73.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 12,114 shares in the last quarter. SG Americas Securities LLC raised its holdings in Fate Therapeutics by 161.2% during the fourth quarter. SG Americas Securities LLC now owns 38,913 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 24,013 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Fate Therapeutics by 106.9% in the first quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 32,911 shares in the last quarter. Institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Price Performance

FATE opened at $1.19 on Friday. The stock has a market capitalization of $137.27 million, a price-to-earnings ratio of -0.90 and a beta of 2.22. The firm has a 50 day moving average price of $1.09 and a 200-day moving average price of $1.14. Fate Therapeutics has a twelve month low of $0.66 and a twelve month high of $1.94.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.63 million. Fate Therapeutics had a negative net margin of 2,187.11% and a negative return on equity of 51.28%. As a group, analysts expect that Fate Therapeutics will post -1.63 earnings per share for the current year.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.